HYDERABAD/BENGALURU (Reuters) – Cipla, one of India’s largest drugmaker by sales, reported a bigger-than-expected third-quarter profit on Tuesday, helped by strong demand, especially in the key North American market.
The company’s consolidated net profit increased nearly 49% to 15.71 billion rupees ($181.6 million) in the October-December quarter, beating analysts’ estimate of 12.12 billion rupees, as per LSEG data.
($1 = 86.5325 Indian rupees)
(Reporting by Rishika Sadam in Hyderabad and Kashish Tandon in Bengaluru; Editing by Eileen Soreng)
Comments